Neoprobe Corporation Regulatory Submission For Lymphoseek; Neoprobe Files Non-Clinical Response With FDA

DUBLIN, Ohio--(BUSINESS WIRE)--Dec. 21, 2005--Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that it has submitted results from seven non-clinical studies of Lymphoseek(TM) to the U.S. Food and Drug Administration (FDA). The studies included genotoxicity studies, an acute toxicity study, repeat dose toxicity studies and a cardiovascular safety pharmacology study. The study results, which appear to provide an adequate safety profile for Lymphoseek, will have to be confirmed by FDA review prior to the commencement of a Phase II study in humans to further evaluate the safety and efficacy of Lymphoseek.

Back to news